États-Unis · Plateformes & données · Stocktwits

Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End

Publié par Stocktwits · États-Unis il y a 8 h

Iovance Biotherapeutics (IOVA) was in the spotlight on Friday after the biotech firm reported promising results from a Phase 2 trial of its experimental cell therapy Lifileucel,…

Lire l'article complet sur Stocktwits Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (stocktwits.com)

Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End

À lire aussi

American Express: 3 Key Takeaways for Long-Term Investors

Genmab A/S (NASDAQ:GMAB) Stock Price Up 7.4% - What's Next?

Flagstar forecasts 2027 EPS of $0.85-$0.95 and shifts full turnaround timeline to 2028 amid higher rates

‘Some people did everything right’: I lost my home in the Great Recession. I rent in my 50s. Why is that judged as failure?

Jana Small Finance Bank Q2 FY27 slides: record profit drives guidance upgrade

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End

Partager

À lire aussi

American Express: 3 Key Takeaways for Long-Term Investors

Genmab A/S (NASDAQ:GMAB) Stock Price Up 7.4% - What's Next?

Flagstar forecasts 2027 EPS of $0.85-$0.95 and shifts full turnaround timeline to 2028 amid higher rates

‘Some people did everything right’: I lost my home in the Great Recession. I rent in my 50s. Why is that judged as failure?

Jana Small Finance Bank Q2 FY27 slides: record profit drives guidance upgrade

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030